文献速递前列腺癌男科与性医学

药企向泌尿外科医生的推广付款与靶向治疗处方模式的关系

Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
PubMed 文献 · Urology · 2020-10-16

该研究基于2015年美国Part D事件文件20%全国样本和Open Payments数据,分析药企向泌尿外科医生支付的推广费用与阿比特龙或恩扎卢胺首次处方医生专科的关系。

要点

  • 市场层面药企对泌尿外科医生的推广付款与泌尿外科医生首次处方阿比特龙或恩扎卢胺强烈相关。
  • 最高付款市场24.3%由泌尿外科医生首次处方,最低付款市场仅5.8%。
  • 其他推广付款指标及市场泌尿外科医生数量与处方专科无关。

核心结论

  • 市场层面对泌尿外科医生的推广付款与阿比特龙或恩扎卢胺首次处方的医生专科强烈相关。

研究设计与样本

  • 使用2015年Part D事件文件20%全国样本识别首次处方阿比特龙或恩扎卢胺的患者及处方医生。
  • 使用2015年Open Payments数据描述市场层面对医生的推广付款。
  • 采用广义线性模型测量市场层面对泌尿外科医生的付款与首次处方医生专科的关系。

主要发现

  • 2015年共有2318名男性由泌尿外科医生或肿瘤内科医生首次处方阿比特龙或恩扎卢胺。
  • 市场内泌尿外科医生数量、对肿瘤内科医生的该药推广付款、对所有医生的其他药物推广付款均与泌尿外科医生首次处方无关。

临床怎么用

  • 关注药企推广付款对泌尿外科医生首次处方阿比特龙或恩扎卢胺的潜在影响。
  • 需进一步评估处方模式变化对晚期前列腺癌患者照护质量和经济负担的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To measure the association between market-level promotional payments to urologists by the manufacturers of abiraterone and enzalutamide and national prescribing patterns. METHODS: A 20% national sample of the 2015 Part D event file was used to identify patients filling their first prescription for abiraterone and enzalutamide and their prescribing physicians. The 2015 Open Payments data were used to characterize promotional payments made to physicians at the market level. Generalized linear models were then used to measure the relationship between market-level payments to urologists and the physician specialty prescribing abiraterone or enzalutamide for the first time RESULTS: In 2015, 2318 men filled a prescription for abiraterone or enzalutamide by a urologist or medical oncologist. Increasing market-level promotional payments to urologists for abiraterone or enzalutamide was strongly associated with a urologist prescribing either drug-24.3% versus 5.8% of those residing in the markets with highest and lowest level of promotional payments to urologists, respectively (P <.01). Neither the number of urologists residing in a market nor other promotional payment measures (ie, to medical oncologists for these drugs, or to all physicians for all other drugs) were associated with a urologist prescribing either drug. CONCLUSION: Promotional payments to urologists at the market level are strongly associated with the specialty of the physician prescribing abiraterone or enzalutamide for the first time. Future work should elucidate the effects of the shift in prescribing patterns on quality of care and financial hardship for men with advanced prostate cancer.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Hollenbeck BK, Oerline M, Kaufman SR, et al. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. Urology. 2020. PMID: 33075381. doi:10.1016/j.urology.2020.08.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。